Malignant gliomas are considered to be among the deadliest of human cancers. Although we have gained detailed knowledge of a number of genetic pathways mutated in gliomas, recent studies suggest additional mutations play significant role in the phenotype and resistance of this disease. The overall goal of the Neuropathology Core is to provide expert, high throughput, and highly integrated tissue based analysis of human and mouse gliomas the P01. The research of each project is heavily based upon the in vtvo biology of human and mouse gliomas, and as such, the Neuropathology Core services are essential for the success of the P01. In addition, the Core strives to improve the services it delivers through the development of emerging tissue technologies that will reduce the difficulties each project encounters in studying increasingly limited tissue resources. Moreover, the centralized nature of the Core will foster intellectual resource sharing and allow investigators to compare and interpret their findings within the spectrum of research performed across all the projects. The Neuropathology Core has three specific aims: 1) to provide pathologic analysis and interpretation of human and mouse gliomas. 2) to characterize human and mouse gliomas using molecular pathology tools. 3) to develop and implement novel technologies for cellular and molecular characterization of human and mouse gliomas. The Core has the requisite neuropathologic expertise, sophisticated resources, and experienced staff to carry out these aims and ensure that the P01 meets its overall goals of discovery of targets for therapy in malignant glioma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
7P01CA095616-10
Application #
8378018
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
2014-02-28
Budget Start
2012-08-14
Budget End
2013-02-28
Support Year
10
Fiscal Year
2012
Total Cost
$195,487
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Schrager-Lavelle, Amanda; Herrera, Leslie A; Maloof, Julin N (2016) Tomato phyE Is Required for Shade Avoidance in the Absence of phyB1 and phyB2. Front Plant Sci 7:1275
Frost, Bess; Bardai, Farah H; Feany, Mel B (2016) Lamin Dysfunction Mediates Neurodegeneration in Tauopathies. Curr Biol 26:129-36
Gilhooly, Neville S; Carrasco, Carolina; Gollnick, Benjamin et al. (2016) Chi hotspots trigger a conformational change in the helicase-like domain of AddAB to activate homologous recombination. Nucleic Acids Res 44:2727-41
Liu, Rui; Yang, Guang; Zhou, Meng-Hua et al. (2016) Flotillin-1 downregulates K(+) current by directly coupling with Kv2.1 subunit. Protein Cell 7:455-60
Leonard, Paul G; Satani, Nikunj; Maxwell, David et al. (2016) SF2312 is a natural phosphonate inhibitor of enolase. Nat Chem Biol 12:1053-1058
Poornima, Gopalakrishna; Shah, Shanaya; Vignesh, Venkadasubramanian et al. (2016) Arginine methylation promotes translation repression activity of eIF4G-binding protein, Scd6. Nucleic Acids Res 44:9358-9368
Falchi, Lorenzo; Newberry, Kate J; Verstovsek, Srdan (2015) New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myeloma Leuk 15 Suppl:S27-33
Green, Adam L; Ramkissoon, Shakti H; McCauley, Dilara et al. (2015) Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro Oncol 17:697-707
Muller, Florian L; Aquilanti, Elisa A; DePinho, Ronald A (2015) Collateral Lethality: A new therapeutic strategy in oncology. Trends Cancer 1:161-173
Lee, Eudocia Q; Reardon, David A; Schiff, David et al. (2015) Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol 17:862-7

Showing the most recent 10 out of 126 publications